These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2239575)

  • 41. [Treatment of prostatic cancer with progestational agents].
    Bouffioux C
    Acta Urol Belg; 1976 Oct; 44(4):336-53. PubMed ID: 1026071
    [No Abstract]   [Full Text] [Related]  

  • 42. Impotence therapy and cancer of the prostate.
    Guinan PD; Sadoughi W; Alsheik H; Ablin RJ; Alrenga D; Bush IM
    Am J Surg; 1976 May; 131(5):599-600. PubMed ID: 58562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer.
    Fowler JE; Whitmore WF
    Cancer; 1982 Apr; 49(7):1373-7. PubMed ID: 7059952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Alternative antiandrogen therapy for advanced prostate cancer].
    Hiroyoshi S; Endo T; Yano M; Naoi M; Kamiya N
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():497-501. PubMed ID: 22208032
    [No Abstract]   [Full Text] [Related]  

  • 45. Successful rechallenge to etoposide after an acute vasomotor response.
    Tester WJ; Cohn JB; Fleekop PD; Rabinowitz MS; Lieberman JS
    J Clin Oncol; 1990 Sep; 8(9):1600-1. PubMed ID: 2391561
    [No Abstract]   [Full Text] [Related]  

  • 46. Ethanol injection therapy for locally invasive prostatic adenocarcinoma.
    Amano H; Goya N; Ryoji O; Yagisawa T; Nakazawa H; Toma H
    Urology; 2002 May; 59(5):771-2. PubMed ID: 11992920
    [No Abstract]   [Full Text] [Related]  

  • 47. Advanced prostatic cancer revisited--35 years later.
    Jacobo E; Culp DA
    J Iowa Med Soc; 1977 Feb; 67(2):52-5. PubMed ID: 839097
    [No Abstract]   [Full Text] [Related]  

  • 48. Perspectives on the clinical management of localized prostate cancer.
    Nelson JB
    Asian J Androl; 2014; 16(4):511-4. PubMed ID: 24589461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generalized bleeding following the treatment of prostatic carcinoma with testosterone and radioactive phosphorus.
    Ellman L
    J Urol; 1973 Sep; 110(3):331-2. PubMed ID: 4725740
    [No Abstract]   [Full Text] [Related]  

  • 50. Response to tamoxifen in drug-resistant prostatic carcinoma.
    El-Arini MO
    Lancet; 1979 Sep; 2(8142):588. PubMed ID: 89595
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase I-II study of high-dose etoposide in patients with refractory breast cancer.
    Fraschini G; Holmes FA; Esparza L; Theriault RL; Buzdar AU; Hortobagyi GN
    Invest New Drugs; 1991 Nov; 9(4):365-7. PubMed ID: 1804815
    [No Abstract]   [Full Text] [Related]  

  • 52. [Effectiveness of continuously administered estrogen on the prostatic carcinoma (author's transl)].
    Takeuchi H; Yamauchi A
    Nihon Hinyokika Gakkai Zasshi; 1978 Dec; 69(12):1552-61. PubMed ID: 745324
    [No Abstract]   [Full Text] [Related]  

  • 53. Tamoxifen in advanced prostatic carcinoma.
    Kóczé A; Székely J
    Lancet; 1980 Mar; 1(8167):539. PubMed ID: 6102254
    [No Abstract]   [Full Text] [Related]  

  • 54. Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Jones WG; Fosså SD; Verbaeys AC; Droz JP; Klijn JG; Boven E; de Pauw M; Sylvester R
    Eur J Cancer; 1990; 26(5):646. PubMed ID: 2144757
    [No Abstract]   [Full Text] [Related]  

  • 55. Acute vasomotor response--a reaction to etoposide.
    Athanassiou AE; Bafaloukos D; Pectasidis D; Dimitriadis M
    J Clin Oncol; 1988 Jul; 6(7):1204-5. PubMed ID: 3079542
    [No Abstract]   [Full Text] [Related]  

  • 56. Apnoea after etoposide.
    Rushing DA; Smith S; Cusic M
    Lancet; 1993 May; 341(8856):1353-4. PubMed ID: 8098489
    [No Abstract]   [Full Text] [Related]  

  • 57. An unusual reaction to etoposide.
    Donegan S
    DICP; 1989 Feb; 23(2):177. PubMed ID: 2728510
    [No Abstract]   [Full Text] [Related]  

  • 58. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.